54718-39-7

Basic information

• Product Name: 2,5,6-Trichloronicotinic acid
• Synonyms: 2,5,6-Trichloronicotinic acid;2,5,6-Trichloro-3-pyridinecarboxylic acid;3-Pyridinecarboxylic acid, 2,5,6-trichloro-;2,5,6-Trichloropyridine-3-carboxylic acid
• CAS NO: 54718-39-7
• Molecular Formula: C₆H₂Cl₃NO₂
• Molecular Weight: 226.44
• Mol File: 54718-39-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 158-161 °C
• Boiling Point: 359.1 °C at 760 mmHg
• Flash Point: 171 °C
• Appearance: /
• Density: 1.728
• Storage Temp.: 2-8°C
• PKA: 1.35±0.32(Predicted)
• CAS DataBase Reference: 2,5,6-Trichloronicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5,6-Trichloronicotinic acid(54718-39-7)
• EPA Substance Registry System: 2,5,6-Trichloronicotinic acid(54718-39-7)

Safety Data

• Hazardous Substances Data: 54718-39-7(Hazardous Substances Data)

Usage

Description

It has been reported that on treatment with lithium aluminium hydride pentafluoropyridine gives 2,5,6-tetrafluoropyridine and that further reduction occurs at the 2-position as expected from a hydride attack.

Uses

2,5,6-tetrachloropyridine belongs to carboxylic acid organic compounds and can be used as pharmaceutical intermediates.

Upstream product

• 4553-62-2 2-methylglutaronitrile 
• 52465-59-5 2,5,6-trichloro-3-chloromethylpyridine 
• 58584-80-8 2,3,6-trichloro-5-(trichloromethyl)pyridine 
• 58584-95-5 2,5,6-trichloro-3-methylpyridine 
• 29553-51-3 3-methyl-piperidine-2,6-dione 

Relevant articles and documents

In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3- carbonitriles as JAK2 kinase inhibitors

Synthesis and biological evaluation of a series of 6-aminopyrazolyl- pyridine-3-carbonitriles as JAK2 kinase inhibitors was reported. Biochemical screening, followed by profile optimization, resulted in JAK2 inhibitors exhibiting good kinase selectivity, pharmacokinetic properties, physical properties and pharmacodynamic effects.

Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na+/H+ exchanger

Pyridine and benzene bioisosteres of amiloride were synthesized and evaluated for their inhibitory potency against the sodium-hydrogen exchanger (NHE) involved in intracellular pH regulation. The inhibition of NHE was determined by using the platelet swelling assay (PSA) in which the swelling of human platelets was induced by their incubation in an acid buffer (pH 6.7). Additionally, the inhibitory potency of the most active compounds was assessed by measuring the inhibition of the EIPA-sensitive 22Na+ uptake (UIA) by human platelets after intracellular acidosis. The results indicated that several benzene derivatives and compounds bearing an carbonylguanidine moiety in the meta position of the pyridine nitrogen were much more potent than amiloride (PSA:IC50=43.5 μM; UIA:IC50=100.1 μM), but less than EIPA, a pyrazine NHE inhibitor (PSA:IC50=0.08 μM; UIA:IC50=0.5 μM). In both biological assays (2-amino-5-bromo-pyridine-3-carbonyl)guanidine (32) was the most active molecule (PSA:IC50=0.8 μM, UIA:IC50=0.8 μM). Our investigations demonstrated that the replacement of the pyrazine ring of amiloride by a pyridine or a phenyl ring improved the NHE inhibitory potency (phenyl >pyridine >pyrazine).

Process for the manufacture of bromopyridines

A novel process for the preparation of 2,4-dibromo-, 2,6-dibromo- and 2,4,6-tribromopyridines, and the new bromopyridines to be obtained therewith, are disclosed. The novel process comprises treating 2,4-dichloro-, 2,6-dichloro- and 2,4,6-trichloropyridines, in an anhydrous organic medium, with gaseous HBr at temperatures between 80° and 130°C, said process being both simple and economical.